One potential limitation of Val-ILs is that the particles loaded with antibodies targeting CD19, CD7, or CD33 might affect not only ALL or AML cells but also healthy hematopoietic cells in BM, including B- and T-lymphocytes, as well as myeloid cells. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.